Activist Elliott begins its long-awaited attack on CEO Emma Walmsley and a GlaxoSmithKline that has 'lost its way'

John Carroll

Editor & Founder

After months of market rumors and speculation, activist investor Elliott has begun its assault on CEO Emma Walmsley with a lengthy manifesto on the need …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Activist Elliott begins its long-awaited attack on CEO Emma Walmsley and a GlaxoSmithKline that has 'lost its way'

John Carroll

Editor & Founder

Sign up to read this article for free.

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

Novartis strikes radiopharma deal with Ratio worth up to $745M

A rare neurological disease is Sage’s last, best hope after failures in depression

Neurogene patient had life-threatening side effect in Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Ac­tivist El­liott be­gins its long-await­ed at­tack on CEO Em­ma Walm­s­ley and a Glax­o­SmithK­line that has 'lost its way'

John Carroll

Editor & Founder

Sign up to read this article for free.

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Activist Elliott begins its long-awaited attack on CEO Emma Walmsley and a GlaxoSmithKline that has 'lost its way'

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

Novartis strikes radiopharma deal with Ratio worth up to $745M

A rare neurological disease is Sage’s last, best hope after failures in depression

Neurogene patient had life-threatening side effect in Rett syndrome study

Are programs with compounded GLP-1s safe for your population?